New Releases from NCBI BookshelfWHO guidelines on the management of advanced HIV disease [Internet].WHO guidelines on the management of advanced HIV disease [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfSarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal).Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfApplying Neurobiological Insights on Stress to Foster Resilience Across Life Stages: Proceedings of a Workshop.Applying Neurobiological Insights on Stress to Foster Resilience Across Life Stages: Proceedings of a Workshop.
Rising rates of stress, anxiety, and depression highlight the need to understand how the brain builds resilience across life stages.
Uncategorized
New Releases from NCBI BookshelfDual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies [Internet].Dual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies [Internet].
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increases in pulmonary vascular resistance and pulmonary arterial pressure, which
Uncategorized
New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: Treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy: Reimbursement Recommendation [Internet].Pembrolizumab (Keytruda): Indication: Treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Keytruda in combination with chemoradiotherapy be reimbursed by public drug plans for the treatment
Uncategorized
New Releases from NCBI BookshelfMirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].Mirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Elahere be reimbursed by public drug plans for the treatment of adults with FR-alpha–positive,
